University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > Treatment > Interactions
Database of Antiretroviral Drug Interactions

Interactions between Lipid-lowering agents and Antiretrovirals

Interactions with Atorvastatin
Antiretroviral (ARV)Dose of ARVDose of AtorvastatinEffect on ARV LevelsEffect on Atorvastatin LevelsPotential Clinical EffectsMechanism of InteractionManagement
Amprenavir60
(APV)(Agenerase)
---Not studied; may increase atorvastatin levelsIncreased atorvastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by amprenavir

Avoid combination if possible; may consider low dose atorvastatin or alternative agents; monitor for myopathy

Alternative Agents:
Pravastatin

Darunavir161, 217
(DRV)(Prezista)
darunavir 300 mg with 100 mg ritonavir BID on days 1-940 mg QD on days 1-4, then 10 mg QD on days 4-7-Atorvastatin AUC: decreased 15%; Cmin: increased 81%; Cmax: decreased 44% (10 mg QD with darunavir/ritonavir compared to atorvastatin 40 mg QD alone)Increased atorvastatin effects (eg, myopathy, rhabdomyolysisInhibition of CYP450 3A4 by darunavir/ritonavir

Consider low dose atorvastatin and titrate to effect; monitor for myopathy. Do not exceed atorvastatin 20mg daily.

Efavirenz213
(EFV)(Sustiva)
600 mg QD on days 4-1810 mg QD on days 0-3 and 15-18No significant changeAtorvastatin AUC: decreased 43%; Atorvastatin and metabolites AUC: decreased 34%Decreased lipid effectsInduction of CYP450 3A4 by efavirenz

May need to increase atorvastatin dose

Elvitegravir/cobicistat717
(Genvoya, Stribild)
---Not studied; expected increase in atorvastatin levelsPossible increased atorvastatin effects-

Initiate with low dose and titrate slowly; monitor for adverse effects

Elvitegravir/ritonavir-boosted protease inhibitor717
--- See individual PIs for specific effects. Atorvastatin levels increased 79% - 836% with ritonavir-boosted PIs. Possible increased atorvastatin adverse effects Inhibition of CYP450 3A4 by ritonavir

Do not coadminister with tipranavir. Use with caution with other PIs - initiate lowest dose and titrate slowly, monitor for adverse effects. Do not exceed 20 mg atorvastatin daily for darunavir.

Antiretroviral (ARV)Dose of ARVDose of AtorvastatinEffect on ARV LevelsEffect on Atorvastatin LevelsPotential Clinical EffectsMechanism of InteractionManagement
Etravirine405
(ETR)(Intelence)
-40 mg QDNo significant changeAtorvastatin AUC: decreased 37% 2-hydroxyatorvastatin AUC: increased 27%; Cmax: increased 76%Decreased atorvastatin effectsInduction of CYP450 3A4 by etravirine

Consider low dose atorvastatin and titrate to effect; monitor for myopathy

Fosamprenavir218
(FPV)(Lexiva)
1400 mg BID or 700 mg fosamprenavir with 100 mg ritonavir BID x 14 days10 mg QDAmprenavir AUC: decreased 27% (on 1400 mg BID); Cmax: decreased 18% (on 1400 mg BID)Atorvastatin AUC: increased 130% (on 1400 mg BID); Cmax: increased 304% (on 1400 mg BID); AUC: increased 153% (on 700/100 mg BID); Cmax: increased 184% (on 700/100 mg BIDIncreased atorvastatin effectsInhibition of CYP450 3A4 by amprenavir

Avoid combination if possible; may consider low dose atorvastatin or alternative agents; monitor for myopathy

Fosamprenavir130
(FPV)(Lexiva)
1400 mg BID x 2 weeks10 mg QD x 4 daysAmprenavir Cmax: decreased 18%; AUC: decreased 27%; Cmin: no significant changeAtorvastatin Cmax: increased 304%; AUC: increased 130%; Cmin: no significant changeIncreased atorvastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by fosamprenavir

Avoid combination if possible; may consider low dose atorvastatin or alternative agents; monitor for myopathy

Fosamprenavir130
(FPV)(Lexiva)
700 mg BID with ritonavir 100 mg BID x 2 weeks10 mg QD x 4 daysNo significant changeAtorvastatin Cmax: increased 184%; AUC: increased 153%; Cmin: increased 73%Increased atorvastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by fosamprenavir

Avoid combination if possible; may consider low dose atorvastatin or alternative agents; monitor for myopathy

Alternative Agents:
Pravastatin

Indinavir16
(IDV)(Crixivan)
---Not studied; may increase atorvastatin levelsIncreased atorvastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by indinavir

Avoid combination if possible; may consider low dose atorvastatin or alternative agents; monitor for myopathy

Alternative Agents:
Pravastatin

Lopinavir/ritonavir216, 78
(LPV/r)(Kaletra)
400 mg/100 mg BID x 14 days20 mg QD x 4 daysNo significant changeAtorvastatin AUC: increased 488%; Cmax: increased 367%; Cmin: increased 128%Increased atorvastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by lopinavir/ritonavir

Avoid combination if possible; may consider low dose atorvastatin or alternative agents; monitor for myopathy

Alternative Agents:
Pravastatin

Antiretroviral (ARV)Dose of ARVDose of AtorvastatinEffect on ARV LevelsEffect on Atorvastatin LevelsPotential Clinical EffectsMechanism of InteractionManagement
Nelfinavir219, 24
(NFV)(Viracept)
--Not studiedAtorvastatin AUC: increased 71%; Cmax: increased 122%Increased atorvastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by nelfinavir

Avoid combination if possible; may consider low dose atorvastatin or alternative agents; monitor for myopathy

Alternative Agents:
Pravastatin

Rilpivirine567
(RPV)(Edurant)
150 mg QD40 mg QDNo significant changeAtorvastatin Cmin: decreased 15%; Cmax: increased 35%--

No dose adjustment necessary

Saquinavir215
(SQV)(Fortovase, Invirase)
400 mg BID with ritonavir 400 mg BID on days 4-1840 mg QD on days 1-4 and 15-18Not studiedAtorvastatin AUC: increased 79%; Cmax: increased 330%Increased atorvastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by saquinavir and ritonavir

Avoid combination if possible; may consider low dose atorvastatin or alternative agents; monitor for myopathy

Alternative Agents:
Pravastatin

Tipranavir154
(TPV)(Aptivus)
500 mg BID with 200 mg ritonavir BID x 7 days10 mg x 1No significant changeAtorvastatin AUC: increased 836%; Cmax: increased 761%; Cmin: increased 419%Orthohydroxy-atorvastatin AUC: decreased 89%; Cmax: decreased 98%; Cmin: decreased 93%Parahydroxy-atorvastatin AUC: decreased 82%; Cmax: no significant change; Cmin: decreased 77%Increased atorvastatin effectsPossible inhibition of CYP450 3A4 by tipranavir/ritonavir

Dose adjustment not established

Alternative Agents:
Pravastatin

"-" indicates that there are no data available
Interactions with Cerivastatin
Antiretroviral (ARV)Dose of ARVDose of CerivastatinEffect on ARV LevelsEffect on Cerivastatin LevelsPotential Clinical EffectsMechanism of InteractionManagement
Indinavir16
(IDV)(Crixivan)
---Not studied; may increase cerivastatin levelsIncreased cerivastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by indinavir

Do not coadminister

Alternative Agents:
Atorvastatin Pravastatin

Lopinavir/ritonavir78
(LPV/r)(Kaletra)
---Not studied; may increase cerivastatin levelsIncreased cerivastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by lopinavir/ritonavir

Do not coadminister

Alternative Agents:
Atorvastatin Pravastatin

Nelfinavir24
(NFV)(Viracept)
---Not studied; may increase cerivastatin levelsIncreased cerivastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by nelfinavir

Do not coadminister

Alternative Agents:
Atorvastatin Pravastatin

"-" indicates that there are no data available
Interactions with Gemfibrozil
Antiretroviral (ARV)Dose of ARVDose of GemfibrozilEffect on ARV LevelsEffect on Gemfibrozil LevelsPotential Clinical EffectsMechanism of InteractionManagement
Lopinavir/ritonavir521
(LPV/r)(Kaletra)
400/100 mg BID600 mg x 1-Gemfibrozil AUC: decreased 41%; Cmax: decreased 33%Decreased gemfibrozil effectsReduced gemfibrozil absorption due to lopinavir/ritonavir

Potential option includes utilizing alternative antiretrovirals; unknown if fenofibrate has same interaction as gemfibrozil

"-" indicates that there are no data available
Interactions with Lovastatin
Antiretroviral (ARV)Dose of ARVDose of LovastatinEffect on ARV LevelsEffect on Lovastatin LevelsPotential Clinical EffectsMechanism of InteractionManagement
Amprenavir60
(APV)(Agenerase)
---Not studied; may increase lovastatin levelsIncreased lovastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by amprenavir

Do not coadminister

Alternative Agents:
Atorvastatin Pravastatin

Atazanavir
(ATV)(Reyataz)
---Not studied; may increase lovastatin levelsIncreased lovastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by atazanavir

Do not coadminister

Alternative Agents:
Atorvastatin (low dose); Pravastatin

Darunavir161
(DRV)(Prezista)
---Not studied; may increase lovastatin levelsIncreased lovastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by darunavir/ritonavir

Do not coadminister

Alternative Agents:
Atorvastatin (low dose)

Elvitegravir/cobicistat623
(Genvoya, Stribild)
----Potentially increased lovastatin effects (e.g. myopathy, rhabdomyolysis)-

Do not coadminister

Alternative Agents:
Atorvastatin Pravastatin

Elvitegravir/ritonavir-boosted protease inhibitor719
---Increased lovastatin levelsIncreased risk of lovastatin adverse effects (rhabdomyolysis, etc.)-

Do not coadminister

Alternative Agents:
Atorvastatin Pravastatin

Antiretroviral (ARV)Dose of ARVDose of LovastatinEffect on ARV LevelsEffect on Lovastatin LevelsPotential Clinical EffectsMechanism of InteractionManagement
Indinavir16, 254
(IDV)(Crixivan)
---Not studied; may increase lovastatin levelsIncreased lovastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by indinavir

Do not coadminister

Alternative Agents:
Atorvastatin Pravastatin

Lopinavir/ritonavir78
(LPV/r)(Kaletra)
- - - Not studied; may increase lovastatin levelsIncreased lovastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by lopinavir/ritonavir

Do not coadminister

Alternative Agents:
Atorvastatin (low dose); Pravastatin

Nelfinavir24
(NFV)(Viracept)
---Not studied; may increase lovastatin levelsIncreased lovastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by nelfinavir

Do not coadminister

Alternative Agents:
Atorvastatin Pravastatin

Saquinavir254
(SQV)(Fortovase, Invirase)
---Increased lovastatin levelsIncreased lovastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by saquinavir

Do not coadminister

Alternative Agents:
Atorvastatin Pravastatin

"-" indicates that there are no data available
Interactions with Pitavastatin
Antiretroviral (ARV)Dose of ARVDose of PitavastatinEffect on ARV LevelsEffect on Pitavastatin LevelsPotential Clinical EffectsMechanism of InteractionManagement
Atazanavir515, 605
(ATV)(Reyataz)
300 mg QD x 5 days4 mg QDNo significant changePitavastatin AUC: increased 31%; Cmax: increased 60%Possibly increased pitavastatin effects-

Start at lowest dose and titrate to effect

Darunavir617
(DRV)(Prezista)
800 mg darunavir with 100 mg ritonavir QD4 mg QDNo significant changePitavastatin AUC: decreased 26%; Cmax: no significant change--

No dose adjustment necessary

Elvitegravir/ritonavir-boosted protease inhibitor603
--No expected effect on ARV levelsStudied with darunavir/ritonavir (pitavastatin AUC decreased 26%), and lopinavir/ritonavir (pitavastatin AUC decreased 20%).Possible decreased pitavastatin efficacy-

No dosage adjustment necessary; monitor and titrate to effect.

Lopinavir/ritonavir573
(LPV/r)(Kaletra)
400/100 mg BID4 mg QDNo significant changePitavastatin AUC: decreased 20%--

No dose adjustment necessary

"-" indicates that there are no data available
Interactions with Pravastatin
Antiretroviral (ARV)Dose of ARVDose of PravastatinEffect on ARV LevelsEffect on Pravastatin LevelsPotential Clinical EffectsMechanism of InteractionManagement
Darunavir587
(DRV)(Prezista)
600 mg BID with 100 mg ritonavir BID on days 12-1840 mg on days 1-4, and days 15-18Not studiedPravastatin AUC: increased 21%; Cmax: increased 23%--

Use lowest possible starting dose, monitor for toxicity and titrate.

Darunavir161
(DRV)(Prezista)
600 mg BID with ritonavir 100 mg BID40 mg x 1-Pravastatin AUC: increased 81% (increased up to 5-fold in some individuals); Cmax: increased 63%Increased pravastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by darunavir/ritonavir

Use lowest possible starting dose, monitor for toxicity and titrate.

Alternative Agents:
Atorvastatin (low dose)

Efavirenz213
(EFV)(Sustiva)
600 mg QD on days 4-1840 mg QD on days 0-3 and 15-18No significant changePravastatin AUC: decreased 40%Decreased lipid effectsInduction of CYP450 3A4 by efavirenz

May need to increase pravastatin dose

Efavirenz90
(EFV)(Sustiva)
600 mg QD x 15 days40 mg QD x 4 daysNo significant changePravastatin AUC: decreased 44%; Cmax: decreased 32%; Cmin: decreased 19%Decreased pravastatin effectsInduction of CYP450 by efavirenz

May need to increase pravastatin dose

Lopinavir/ritonavir216, 78
(LPV/r)(Kaletra)
400 mg/100 mg BID x 14 days20 mg QD x 4 daysNo significant changePravastatin AUC: increased 33%; Cmax: increased 26%-Unknown

No dose adjustment necessary

Antiretroviral (ARV)Dose of ARVDose of PravastatinEffect on ARV LevelsEffect on Pravastatin LevelsPotential Clinical EffectsMechanism of InteractionManagement
Nelfinavir215
(NFV)(Viracept)
1250 mg BID on days 1-1840 mg QD on days 15-18Nelfinavir AUC: no significant change; Cmin: increased 61%; M8 AUC: no significant change; M8 Cmin: increased 31%Not studied-Unknown

No dose adjustment necessary

Nelfinavir214
(NFV)(Viracept)
Not reportedNot reportedNot reportedPravastatin AUC: decreased 47%Decreased pravastatin effectsPossible induction of CYP450 by nelfinavir

May need to titrate pravastatin dose to effect in order to reach lipid goals

Raltegravir457
(RAL)(Isentress)
400 mg BID40 mg QDRaltegravir AUC: no significant change; Cmax: increased 31%; Cmin: decreased 41%No significant change--

No dose adjustment necessary

Raltegravir465
(RAL)(Isentress)
400 mg BID40 mg QDRaltegravir Cmax: increased 31%; Cmin: decreased 41%No significant change--

No dose adjustment necessary

Saquinavir215
(SQV)(Fortovase, Invirase)
400 mg BID with ritonavir 400 mg BID on days 4-1840 mg QD on days 1-4 and 15-18Not studiedPravastatin AUC: decreased 50%; Cmax: decreased 42%Decreased pravastatin effectsInduction of glucuronidation by ritonavir

No dose adjustment necessary

"-" indicates that there are no data available
Interactions with Rosuvastatin
Antiretroviral (ARV)Dose of ARVDose of RosuvastatinEffect on ARV LevelsEffect on Rosuvastatin LevelsPotential Clinical EffectsMechanism of InteractionManagement
Atazanavir411
(ATV)(Reyataz)
300 mg atazanavir QD with ritonavir 100 mg QD10 mg QD-Rosuvastatin AUC: increased 213%; Cmax: increased 600%Increased rosuvastatin effectsPossibly atazanavir induced increase in rosuvastatin bioavailability

Initiate lowest dose and titrate carefully. Do not exceed 10mg rosuvastatin daily.

Alternative Agents:
Pravastatin, atorvastatin

Darunavir523
(DRV)(Prezista)
600 mg BID with ritonavir 100 mg BID10 mg QDNo significant changeRosuvastatin AUC: increased 48%; Cmax: increased 144%No change in lipid lowering ability within 35 day study period-

Avoid coadministration if possible; if used, use caution and start at 5 mg daily

Elvitegravir/cobicistat639
(Genvoya, Stribild)
Elvitegravir 150 mg QD with COBI 150 mg QD10 mg x 1No significant changeRosuvastatin AUC: increased 38%; Cmax: increased 89%Potentially increased rosuvastatin effects-

Initiate rosuvastatin at lowest dose and titrate carefully. Monitor for adverse effects.

Elvitegravir/ritonavir-boosted protease inhibitor723
--No effect expectedAtazanavir/ritonavir AUC increases 3-fold. Lopinavir/ritonavir increases AUC 108%. Darunavir/ritonavir increases AUC 48%. Tipranavir/ritonavir increases AUC 26%. Rosuvastatin Cmax increased 123-700% when combined with above listed agents.Increased rosuvastatin effects; potential increased risk of myopathyInhibition of CYP450 3A4 by ritonavir

Initiate rosuvastatin at lowest dose and titrate carefully. Monitor for adverse effects. Do not exceed 10mg rosuvastatin daily if administering with lopinavir/ritonavir or atazanavir/ritonavir.

Fosamprenavir411
(FPV)(Lexiva)
700 mg BID with ritonavir 100 mg BID10 mg QD-Rosuvastatin Cmax: increased 45%--

No dose adjustment necessary

Lopinavir/ritonavir170
(LPV/r)(Kaletra)
400/100 mg BID on days 8-2420 mg QD on days 1-7, 18-24Not studiedRosuvastatin AUC: increased 108%; Cmax: increased 366%; Cmin: no significant changeIncreased rosuvastatin effects-

Initiate lowest dose and titrate carefully. Do not exceed 10mg rosuvastatin daily.

Alternative Agents:
Pravastatin; atorvastatin

Tipranavir166
(TPV)(Aptivus)
500 mg BID with 200 mg ritonavir BID10 mgTipranavir Cmin: increased 23%; Ritonavir AUC: increased 15%; Cmax: increased 25%; Cmin: increased 23%Rosuvastatin AUC: increased 37%; Cmax: increased 123%; Cmin: decreased 12%Increased rosuvastatin effects-

Avoid coadministration if possible; if used, use caution and start at 5 mg daily

"-" indicates that there are no data available
Interactions with Simvastatin
Antiretroviral (ARV)Dose of ARVDose of SimvastatinEffect on ARV LevelsEffect on Simvastatin LevelsPotential Clinical EffectsMechanism of InteractionManagement
Amprenavir60
(APV)(Agenerase)
---Not studied; may increase simvastatin levelsIncreased simvastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by amprenavir

Do not coadminister

Alternative Agents:
Atorvastatin Pravastatin

Atazanavir
(ATV)(Reyataz)
--- Not studied; may increase simvastatin levelsIncreased simvastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by atazanavir

Do not coadminister

Alternative Agents:
Atorvastatin (low dose); Pravastatin

Darunavir161
(DRV)(Prezista)
---Not studied; may increase simvastatin levelsIncreased simvastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by darunavir/ritonavir

Do not coadminister

Alternative Agents:
Atorvastatin (low dose)

Efavirenz213
(EFV)(Sustiva)
600 mg QD on days 4-1840 mg QD on days 0-3 and 15-18No significant changeSimvastatin AUC: decreased 58%Decreased lipid effectsInduction of CYP450 3A4 by efavirenz

May need to increase simvastatin dose

Efavirenz90
(EFV)(Sustiva)
600 mg x 15 days40 mg QD x 4 daysNo significant changeSimvastatin AUC: decreased 68%; Cmax: decreased 72%; Cmin: decreased 45%Decreased simvastatin effectsInduction of CYP450 by efavirenz

May need to increase simvastatin; Given interaction potential between simvastatin and protease inhibitors, consider avoiding efavirenz and simvastatin in case patient's antiretroviral regimen is changed and simvastatin is not changed to another statin

Antiretroviral (ARV)Dose of ARVDose of SimvastatinEffect on ARV LevelsEffect on Simvastatin LevelsPotential Clinical EffectsMechanism of InteractionManagement
Elvitegravir/cobicistat623
(Genvoya, Stribild)
----Potentially increased simvastatin effects (e.g. myopathy, rhabdomyolysis)-

Do not coadminister

Elvitegravir/ritonavir-boosted protease inhibitor725
--No effect expectedNot studied with PIs used with elvitegravir/ritonavir. Significant increase in simvastatin levels expected.Possible increased risk of simvastatin adverse effects (e.g. myopathy)Inhibition of CYP450 3A4 by ritonavir

Do not coadminister

Indinavir16, 254
(IDV)(Crixivan)
---Increased simvastatin levelsIncreased simvastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by indinavir

Do not coadminister

Alternative Agents:
Atorvastatin Pravastatin

Lopinavir/ritonavir78
(LPV/r)(Kaletra)
---May increase simvastatin levelsIncreased simvastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by lopinavir/ritonavir

Do not coadminister

Alternative Agents:
Atorvastatin Pravastatin

Nelfinavir219, 24
(NFV)(Viracept)
--No significant changeSimvastatin AUC: increased 506%; Cmax: increased 517%Increased simvastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by nelfinavir

Do not coadminister

Alternative Agents:
Atorvastatin Pravastatin

Saquinavir254
(SQV)(Fortovase, Invirase)
---Increased simvastatin levelsIncreased simvastatin effects (eg, myopathy, rhabdomyolysis)Inhibition of CYP450 3A4 by saquinavir

Do not coadminister

Alternative Agents:
Atorvastatin Pravastatin

Saquinavir215
(SQV)(Fortovase, Invirase)
400 mg BID with ritonavir 400 mg BID on days 4-1840 mg QD on days 1-4 and 15-18-Simvastatin AUC: increased 3059%; Cmax: increased 3000%Increased simvastatin effectsInhibition of CYP450 3A4 by saquinavir and ritonavir

Do not coadminister

Alternative Agents:
Atorvastatin Pravastatin

"-" indicates that there are no data available
 16:Crixivan [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; Oct 2005.
 24:Viracept [package insert]. La Jolla, CA: Agouron Pharmaceuticals, Inc.; Sept 2004.
 60:Agenerase [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc; 2004.
 78:Kaletra [package insert]. North Chicago, IL: Abbott Laboratories; Oct 2005.
 90:Sustiva [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; Dec 2011.
 130:Lexiva [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc; Nov 2005.
 154:Aptivus [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov 2005.
 161:Prezista [package insert]. Raritan, NJ: Tibotec Therapeutics Inc.; April 2010.
 166:Pham PA, Lee L, Fuchs E, et al. Pharmacokinetic interaction between tipranavir/ritonavir and rosuvastatin [poster #767]. 13th Conference on Retroviruses and Opportunistic Infections; 2008 February 3-6; Boston, Massachusetts.
 170:Hoody DW, Kiser JJ, et al. Drug-drug interaction between lopinavir/ritonavir and rosuvastatin [poster #564]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25-28; Los Angeles, California.
 213:Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin and pravastatin: results of ACTG 5108 study. J Acquir Immune Defic Syndr 2005; 39: 307-12.
 214:Gerber JG, Rosenkranz S, Fichtenbaum CJ, et al. The effect of efavirenz and nelfinavir on the pharmacokinetics of pravastatin [abst 870]. 2nd International Conference on HIV Pathogenesis and Treatment; 2003 July 13-16; Paris, France.
 215:Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interaction between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047. AIDS 2002;16:569-77.
 216:Carr RA, Andre AK, Bertz RJ, et al. Concomitant administration of ABT-378/ritonavir (ABT-378/r). Results in a clinically important pharmacokinectic (PK) interaction with atorvastatin but not pravastatin [abstract #1644]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 September 17-20; Toronto, Canada.
 217:Hoetelmans R, Lasure A, Koester A, et al. The effect of TMC114, a potent next-generation HIV protease inhibitor, with low-dose ritonavir on atorvastatin pharmacokinetics [poster #H-865]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 October 30-November 2; Washington, D.C.
 218:Wire MB, Baker KL, Moore KHP, et al. The pharmacokinetic (PK) interaction of GW433908 (908) with atorvastatin (ATO) and 908/ritonavir (RTV) with ATO (APV10013) [abstract #A-1622]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois.
 219:Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001;45:3445-50.
 254:CDC. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Jan 28, 2000. [AIDS Treatment Information Service: Current Treatment] Available at: http://www.hivatis.org/trtgdlns.html.
 405:Intelence [package insert]. Raritan, NJ: Tibotec Therapeutics; 2010.
 411:Busti AJ, Bain AM, Hall RG 2nd, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardovasc Pharmacol 2008; 51: 605-10.
 457:Van Luin M, Colbers EPH, Verwey-van Wissen CPWGM, et al. Drug-drug interactions between raltegravir and pravastain in healthy volunteers poster 29]. 11th International Workshop on Clinical Pharmacology of HIV Therapy, April 7-9, 2010; Sorrento, Italy.
 465:Van Luin M, Colbers A, Van Ewijk-Beneken Kolmer EW, et al. Drug-drug interactions between raltegravir and pravastatin in healthy volunteers. J Acquir Immune Defic Syndr 2010; April 15.
 515:Reyataz [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, March 2012.
 521:Busse KH, Hadigan C, Chairez C, et al. Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir. J Acquir Immune Defic Syndr 2009; 52: 235-39.
 523:Fichtenbaum C, Samineni D, Moore E, e tal. Darunavir/ritonavir incresaes rosuvastatin concentrations but does not alter lipid-lowering effect in healthy volunteers [poster WePE0101]. 18th International AIDS Conference, July 18-23, 2010; Vienna, Austria.
 567:Edurant [package insert]. Raritan, NJ: Tibotec Therapeutics Inc.; May 2011.
 573:Morgan R, Campbell S, Suehira K, et al. Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers [MOPE170]. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17-20 July, 2011; Rome, Italy.
 587:Aquilante CL, Kiser JJ, Anderson PL, et al. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. J Clin Pharmacol 2011. 1-12. [Epub ahead of print].
 603:Livalo [package insert]. Montgomery, AL: Kowa Pharmaceuticals America, Inc.; February 2012.
 605:Livalo [package insert]. Montgomery, AL: Kowa Pharmaceuticals America, Inc.; Feb 2012.
 617:Yu CY, Campbell SE, Sponseller CA, et al. Steady state pharmacokinetic Interactions of darunavir/ritonavir with pitavastatin in healhty adult volunteers [TUPE053]. 19th International AIDS Conference, July 22-27, 2012; Washington, D.C.
 623:Stribild [package insert]. Foster City, CA: Gilead Sciences, Inc.; August 2012.
 639:DHHS. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Feb 12, 2013.
 717:Stribild [package insert]. Foster City, CA: Gilead Sciences, Inc.; Feb 2016
 719:Tybost [package insert]. Foster City, CA: Gilead Sciences, Inc.; Nov 2015
 723:Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
 725: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.